Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan PK in Hepatic Impairment
NCT03212131Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2017
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of somapacitan in growth hormone deficiency (GHD) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the somapacitan serum concentration time curve. Started Aug 2017; status: completed.
02
Drugs
somapacitan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT03212131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03212131.